Literature DB >> 984066

Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies.

L I Lutwick, J N Galgiani, R H Johnson, D A Stevens.   

Abstract

Four patients with visceral infections due to the fungus Petriellidium boydii, who were recently hospitalized in our institutions, are described. Three of the patients were compromised hosts; in the fourth patient, infection occurred after trauma. All had received prior steroid and antibiotic therapy. Studies of patients with mycetoma or secondary infection of a pulmonary cavity due to this organism and of patients with visceral infections are reviewed. Because of histologic similarities to Aspergillus species, infections due to P. boydii may have been misdiagnosed in the past if the infecting fungus was not isolated in culture. The fungus has been shown to be resistant in vitro to currently available antifungal agents. Resistance to amphotericin and 5-fluorocytosine is demonstrated in our studies. There are few reports of successful chemotherapy of any manifestation of this infection, and no such reports of visceral disease. We demonstrate in vitro sensitivity of isolates in our cases and in others to micronazole, a new antimicrobial agent; this drug may be indicated for treatment of disease due to P. boydii.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984066     DOI: 10.1016/0002-9343(76)90141-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  26 in total

1.  In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.

Authors:  E M Johnson; A Szekely; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 3.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

4.  Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy.

Authors:  P E Verweij; N J Cox; J F Meis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

5.  Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.

Authors:  C Girmenia; G Luzi; M Monaco; P Martino
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

6.  Invasive pulmonary pseudallesheriosis in a cross-breed calf.

Authors:  R V Pawaiya; K Charan; A Sikdar; N S Parihar
Journal:  Mycopathologia       Date:  1994-10       Impact factor: 2.574

Review 7.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Mycotic osteomyelitis due to Scedosporium Apiospermum: MR imaging-pathologic correlation.

Authors:  Malcolm K Sydnor; Shaifali Kaushik; Thomas E Knight; C Lee Bridges; John M McCarty
Journal:  Skeletal Radiol       Date:  2003-09-23       Impact factor: 2.199

Review 9.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 10.  Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.